Focal cerebral ischaemia induces a decrease in activity and a shift in ouabain affinity of Na+, K+-ATPase isoforms...

Area of Science:

• Neuroscience
• Biochemistry
• Cardiovascular Research

Background:

• Na+, K+-ATPase is crucial for maintaining cellular ion gradients and neuronal function.
• Cerebral ischemia, a disruption of blood flow to the brain, can lead to significant cellular damage.
• Understanding the molecular mechanisms affected by ischemia is vital for developing therapeutic strategies.

Purpose of the Study:

• To investigate the impact of focal cerebral ischemia on Na+, K+-ATPase activity and ouabain binding characteristics in a mouse model.
• To determine if changes in protein or mRNA expression of Na+, K+-ATPase isoforms occur following ischemic events.
• To elucidate the specific alterations in Na+, K+-ATPase function induced by cerebral ischemia.

Main Methods:

• Induction of focal cerebral ischemia in a mouse model.
• Measurement of total Na+, K+-ATPase activity at various time points post-occlusion.
• Analysis of ouabain dose-response curves to characterize inhibitory binding sites.
• Assessment of protein and mRNA expression levels for Na+, K+-ATPase alpha and beta isoforms.

Main Results:

• Total Na+, K+-ATPase activity decreased by 39.4% after 1 hour of ischemia and remained significantly reduced up to 6 hours.
• In ischemic animals, only two ouabain inhibitory sites were detected, compared to three in sham controls.
• The affinity of the remaining ouabain binding sites shifted post-ischemia, with one site showing low affinity and the other evolving towards very high affinity.
• The reduced activity of the second ouabain binding site fully accounted for the overall loss in Na+, K+-ATPase activity.
• No significant changes in protein or mRNA expression of Na+, K+-ATPase isoforms were observed.

Conclusions:

• Focal cerebral ischemia induces significant alterations in Na+, K+-ATPase activity and its ouabain binding properties.
• The observed changes suggest intrinsic modifications to the Na+, K+-ATPase enzyme itself, rather than alterations in gene or protein expression.
• These findings highlight a potential molecular target for therapeutic intervention in ischemic stroke.